20 years ahead of the industry

Focused. Proven. Ready to license.

Whether you’re launching a new range, expanding or improving your current formulas, Seipel Group gives you a faster path to proven results — with patented, clinically validated solutions built for today’s supplement brands.

It started with a question no one was asking:

Why was bladder weakness so common, yet so underserved?

Two decades ago, Dr. Tracey Seipel recognized that bladder control issues were affecting women far earlier in life than most realized. Despite the prevalence, there were no natural options with clinical evidence.

Dr. Seipel formulated the first herbal bladder support product of its kind — and rather than rely on anecdote, she pursued clinical trials, scientific validation, and real-world use in clinic. That commitment to evidence laid the foundation for Seipel Group’s entire philosophy.

Dr. Tracey Seipel

N.D., CEO, Seipel Group

From concept to global category leader

Two decades of research, refinement, and results.

What began as a first-of-its-kind formulation in Australia is now one of the most clinically validated bladder health solutions on the market — supported by years of published trials and continuous development.

1999

First Bladder Control Formulation

Launched in Australia

2002

Early Pilot Trial

Shows improvements using Crateva and horsetail. (Steels et al.)

2004

Formula Refined

Formula refined to increase effectiveness.

2006

Large-scale Randomized Controlled Trial

Confirms improvements in urgency, frequency, and nocturia. (Schauss et al.)

2010

Reformulation

Reformulated for faster results at a lower daily dose.

2011

Pilot Trials

Urox® shown to reduce symptoms of incontinence and overactive bladder.

2012

Further Formula Improvements

Proprietary lindera extract added to enhance speed and consistency of results.

2018

Large-scale Randomized Controlled Trial

150 participants saw improvements within 2–4 weeks. (Schoendorfer et al.)

2021

Children’s Randomized Control Trial

Urox® Junior reduces bedwetting and daytime accidents. (Schloss et al.):

2022

Mechanism of Action Trial

Urox® shown to have multiple mechanisms demonstrating its broad efficacy.

A mission grounded in results.

Improving lives through function, not just promise or “containment”.

From the beginning, our purpose has been to support better bladder health — and the freedom, confidence, and dignity that come with it.

We don’t chase trends. We invest in research. We create formulations that deliver measurable change, and we partner with brands that share our belief in doing things right.

Why it matters to your brand and your customers

The market is underserved. The demand is growing.

Urinary incontinence cost the U.S. $19.5 billion as early as 2000. Today, consumers spend nearly $9 billion annually on disposable pads and diapers, plus billions more on treatments with limited success.

At the same time, over 75% of those with overactive bladder have tried natural remedies — but most of what’s available is under-powered, under-researched, and ineffective.